Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

XOMA Royalty stock

XOMA
US98419J2069
A2ATUH

Price

30.58
Today +/-
+0.35
Today %
+1.24 %
P

XOMA Royalty stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the XOMA Royalty stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the XOMA Royalty stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the XOMA Royalty stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze XOMA Royalty's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

XOMA Royalty Stock Price History

DateXOMA Royalty Price
11/8/202430.58 undefined
11/7/202430.20 undefined
11/6/202432.46 undefined
11/5/202431.02 undefined
11/4/202430.86 undefined
11/1/202430.38 undefined
10/31/202430.20 undefined
10/30/202429.86 undefined
10/29/202431.93 undefined
10/28/202430.22 undefined
10/25/202429.51 undefined
10/24/202429.50 undefined
10/23/202429.12 undefined
10/22/202428.65 undefined
10/21/202428.46 undefined
10/18/202429.40 undefined
10/17/202428.84 undefined
10/16/202429.48 undefined
10/15/202428.70 undefined
10/14/202428.23 undefined
10/11/202427.59 undefined
10/10/202426.81 undefined

XOMA Royalty Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into XOMA Royalty, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by XOMA Royalty from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects XOMA Royalty’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of XOMA Royalty. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into XOMA Royalty’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing XOMA Royalty’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on XOMA Royalty’s growth potential.

XOMA Royalty Revenue, EBIT and net profit per share

DateXOMA Royalty RevenueXOMA Royalty EBITXOMA Royalty Net Income
2026e48.29 M undefined11.08 M undefined1.17 M undefined
2025e35.69 M undefined33,996.6 undefined-7.01 M undefined
2024e28.01 M undefined-16.18 M undefined-1.43 M undefined
20234.76 M undefined-26.02 M undefined-46.3 M undefined
20226.03 M undefined-17.41 M undefined-22.58 M undefined
202138.16 M undefined17.53 M undefined7.97 M undefined
202029.39 M undefined12.42 M undefined9.01 M undefined
201918.37 M undefined-3.89 M undefined-1.98 M undefined
20185.3 M undefined-14.95 M undefined-13.34 M undefined
201752.69 M undefined20.48 M undefined5.71 M undefined
20165.56 M undefined-56.99 M undefined-53.53 M undefined
201555.45 M undefined-36.02 M undefined-20.61 M undefined
201418.87 M undefined-81.75 M undefined-38.3 M undefined
201335.45 M undefined-57.88 M undefined-124.06 M undefined
201233.78 M undefined-51.55 M undefined-71.07 M undefined
201158.2 M undefined-33.96 M undefined-32.74 M undefined
201033.64 M undefined-67.02 M undefined-68.7 M undefined
200998.43 M undefined16.57 M undefined550,000 undefined
200867.99 M undefined-38.74 M undefined-45.25 M undefined
200784.25 M undefined-2.54 M undefined-12.33 M undefined
200629.5 M undefined-40.68 M undefined-51.84 M undefined
200518.67 M undefined-36.03 M undefined2.78 M undefined
20043.67 M undefined-78.1 M undefined-78.94 M undefined

XOMA Royalty Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
57089102017501131862617292431829846798335833351855552518293864263447
-40.00--12.5011.11100.00-15.00-70.59---200.00500.00-66.67-66.67200.00183.3370.59-17.24-87.50500.0061.11189.66-20.2446.27-66.3375.76-43.106.06-48.57205.56-90.91940.00-90.38260.0061.1131.03-84.21-33.33550.0030.7738.24
100.00100.00-100.00100.0090.0065.0047.0640.00-100.00---------------100.00----------------
570899138201000000000000000330000000000000000
-3-5-15-17-15-22-24-41-38-34-34-26-28-17-45-45-29-27-32-57-78-36-40-2-3816-67-33-51-57-81-36-5620-14-31217-17-26-16011
-60.00-71.43--212.50-166.67-220.00-120.00-241.18-760.00--3,400.00-2,600.00-933.33-94.44-750.00-2,250.00-483.33-158.82-110.34-237.50-2,600.00-200.00-137.93-2.38-56.7216.33-203.03-56.90-154.55-162.86-450.00-65.45-1,120.0038.46-280.00-16.6741.3844.74-283.33-650.00-61.54-23.40
-3-4-46-15-12-18-23-34-47-31-34-23-29-17-49-45-29-28-33-58-782-51-12-450-68-32-71-124-38-20-535-13-197-22-46-1-71
-33.331,050.00-67.39-20.0050.0027.7847.8338.24-34.049.68-32.3526.09-41.38188.24-8.16-35.56-3.4517.8675.7634.48-102.56-2,650.00-76.47275.00---52.94121.8874.65-69.35-47.37165.00-109.43-360.00-92.31-1,000.00-22.22-414.29109.09-97.83600.00-114.29
0.010.020.020.040.040.040.050.060.070.070.070.080.110.130.140.180.220.230.230.250.280.30.320.430.440.570.931.583.234.355.375.896.027.988.378.7611.512.1911.4111.47000
-------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The XOMA Royalty Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the XOMA Royalty is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                             
8.540.560.255.491.372.1124.383.470.239.726.44755.128.318.535.267.636.785.224.343.546.438.610.823.937.348.385.3121.678.466.325.743.545.856.784.294.158.2153.45
0000.60.600000.30.30.30.30.20.20.22.18.910.70.94.911.611.716.36.420.311.87.53.73.33.70.50.41.52.90.30.201
0.30.61.224.94.24.20.91.10.62.60.50.10.20.7100000.40.40.40.40.80.60.50.70.100.40.10001.502.414.22
00001.28.110.45.54.24.20000001.31.3000000000000000000000
0.20.70.80.80.60.70.60.810.80.20.20.10.20.70.20.21.91.31.41.56.17.411.210.722.31.61.91.90.90.30.40.422.60.70.64
941.862.258.898.685.1139.590.676.545.629.54855.628.920.136.671.248.897.226.650.364.558.138.732.158.962.695.812783.672.327.244.247.7608896.961.3169.31
5.74.53.57.89.29.714.718.517.515.46.25.14.63.93.78.414.622.721.319.319.122.425.626.820.314.912.78.16.55.1210.10.10.50.40.200.4
0000000000000000000000000000000000.40.71.7000
000000000000000000.20.10.20.1000000000000034.434.669.163.757.95
000000000000000000000000000000000000015.20
000000000000000000000000000000000000000
0.110.70.62.62.10.10.10.11.55.24.64.64.64.60.20.20.20.20.23.13.21.11.60.40.52.61.71.30.70.70.50.715.70.20.60.30.36.63
5.85.54.28.411.811.814.818.617.616.911.49.79.28.58.38.614.823.121.619.722.325.626.728.420.715.415.39.87.85.82.71.50.816.235.837.369.679.264.99
14.847.366.467.2110.496.9154.3109.294.162.540.957.764.837.428.445.28671.9118.846.372.690.184.867.152.874.377.9105.6134.889.47528.74563.995.8125.3166.5140.5234.3
                                                                             
0.20000000000006.400000000.10.10.10.10.20.30.60.80.90.900.10.10.10.10.10.10.14
0.030.070.110.140.140.160.310.310.330.330.330.370.390.40.430.470.520.530.650.650.660.690.740.750.80.880.90.981.081.121.141.151.181.211.241.271.311.311.31
-16-62.6-74.8-94.1-113-136.7-171-218.1-249.4-284.8-307.9-337.2-354.5-404.3-450.2-479.6-507.6-540.9-599.5-678.5-675.7-727.5-739.9-785.1-784.6-853.3-886.1-957.1-1,081.2-1,119.5-1,140.1-1,193.6-1,179.1-1,192.4-1,194.4-1,181.1-1,165.3-1,182.4-1,223.22
-300-1000000000000000-100100100200300-100000000000000000000
000000000000000000000000000000000000000
13.31238.541.427.126.4134.588.578.443.526.834.731.20.2-16.9-8.613.7-11.448.2-24.7-20.8-38.10.3-31.417.523.61521.5-43.1-2.3-47.25.818.84486.4141.812488.72
0.80.511.32.16.6510.51.42.11.81.63.53.92.53.53.25.11.95.64.27102.93.62.13.99.666.85.71.71.20.60.51.10.50.65
0.41.41.31.72.63.712.98.55.78.73.76.16.46.76.54.34.47.16.219.36.68.98.668.610.71013.21210.17.48.12.72.31.10.80.732.82
01.10.90.81.81.10000000003.351.70.124.38.28117.121.36.13.42.21.13.20.93.11.422.911.23.310.48
000000000000000000.813.30.10000000000000000000
0.10.20.20.10.20.30.40.40.60.30.50.50.70.300.25.75.85.80.20000002.83.45.8195.917.900.85.28.1005.54
1.33.23.43.96.711.718.39.96.810.46.38.48.710.510.410.318.618.630.523.516.521.323.62718.635.62123.929.636.223.332.67.55.78.912.3136.819.5
0.232.224.721.876.758.91.51.10.40.17.714.524.826.534.739.852.463.740.240.972.498.250.963.313.313.733.537.735.216.342.825.314.621.727.112.800118.52
000000000000000000000000000000000000000
00000009.98.58.5000003.61.50.806.34.38.8108.33.31.48.522.77433.811.118.117.217.615.813.811.79.67.56
0.232.224.721.876.758.91.5118.98.67.714.524.826.534.743.453.964.540.247.276.710760.971.616.615.14260.4109.250.153.943.431.839.342.926.611.79.6126.08
1.535.428.125.783.470.619.820.915.7191422.933.53745.153.772.583.170.770.793.2128.384.598.635.250.76384.3138.886.377.27639.34551.838.924.716.4145.58
14.847.466.667.1110.597154.3109.494.162.540.857.664.737.228.245.186.271.7118.94672.490.284.867.252.774.378105.8134.889.474.928.845.163.895.8125.3166.5140.4234.3
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of XOMA Royalty provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand XOMA Royalty's financial health and stability.

Assets

XOMA Royalty's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that XOMA Royalty must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of XOMA Royalty after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into XOMA Royalty's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-46-15-12-18-23-34-47-31-34-22-29-15-47-45-29-28-33-58-782-51-12-450-68-32-71-124-38-20-5314-13-11315-17-40
12111132322211112345566655421100000000
00000000000000000000000000000000000000
100-1043-12-11414150-6-128-1234-1-72-865-8-119-8-2-4000-3
31000006106003-403371-39105121212142475-22063710013734
02136200000000000002334500113120000000
00000000000000000000000500000000100000
-12-12-11-18-22-27-33-28-28-24-22-11-37-47-23-22-34-47-44-44-334-327-52-29-40-45-78-30-332-1201022-12-18
0-1-4-2-1-6-6-1-10-1-100-1-7-10-2-2-4-8-9-800-3-2-100000000-150
-31-60-3729-673131929-4026015-1-7-110-2-27-8-83100-3-421819401-15-190-26-200
-30-54-3530-6038331030-392711600-110-2200111000-392020401-15-190-26-40
00000000000000000000000000000000000000
0005500000513901061379-186848-19-500282-3-513-7-1678-5-210130
453001586017043012122834487875000749701577864100312222294120
45300564860170114321113840611597-136848-116-3664379833513-61329301912-4120
0000000001,0000000000000000-2,000-4,000000000-2,00000-4,000-3,000-1,000-4,000
00000000000000000000000000000000000-3-5-5
111-10011-8-220-1916-1936-2561632-3148-61-37-5-12141311-356-23-12-4017210299-37101
-13.03-13.22-15.9-20.31-24.15-34.02-40.78-30.65-29.84-25.1-23.48-13.51-38.63-48.56-24.68-29.78-44.97-50.52-47.47-49.03-41.78-4.93-41.047.17-52.88-32.36-43.28-47.09-78.61-31.32-33.752.68-12.65-0.2910.0822.68-28.13-18.18
00000000000000000000000000000000000000

XOMA Royalty stock margins

The XOMA Royalty margin analysis displays the gross margin, EBIT margin, as well as the profit margin of XOMA Royalty. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for XOMA Royalty.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the XOMA Royalty's sales revenue. A higher gross margin percentage indicates that the XOMA Royalty retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the XOMA Royalty's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the XOMA Royalty's total revenue generated. When comparing the revenue margin year over year, investors can gauge the XOMA Royalty's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the XOMA Royalty. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the XOMA Royalty's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

XOMA Royalty Margin History

XOMA Royalty Gross marginXOMA Royalty Profit marginXOMA Royalty EBIT marginXOMA Royalty Profit margin
2026e100 %22.95 %2.42 %
2025e100 %0.1 %-19.63 %
2024e100 %-57.79 %-5.11 %
2023100 %-546.87 %-973.16 %
2022100 %-288.72 %-374.46 %
2021100 %45.94 %20.89 %
2020100 %42.26 %30.66 %
2019100 %-21.18 %-10.78 %
2018100 %-282.08 %-251.7 %
2017100 %38.87 %10.84 %
2016100 %-1,025 %-962.77 %
2015100 %-64.96 %-37.17 %
2014100 %-433.23 %-202.97 %
2013100 %-163.27 %-349.96 %
2012100 %-152.61 %-210.39 %
2011100 %-58.35 %-56.25 %
2010100 %-199.23 %-204.22 %
2009100 %16.83 %0.56 %
2008100 %-56.98 %-66.55 %
2007100 %-3.01 %-14.64 %
2006100 %-137.9 %-175.73 %
2005100 %-192.98 %14.89 %
2004100 %-2,128.07 %-2,150.95 %

XOMA Royalty Stock Sales Revenue, EBIT, Earnings per Share

The XOMA Royalty earnings per share therefore indicates how much revenue XOMA Royalty has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue XOMA Royalty earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates XOMA Royalty's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of XOMA Royalty’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating XOMA Royalty's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

XOMA Royalty Revenue, EBIT and net profit per share

DateXOMA Royalty Sales per ShareXOMA Royalty EBIT per shareXOMA Royalty Earnings per Share
2026e4.13 undefined0 undefined0.1 undefined
2025e3.05 undefined0 undefined-0.6 undefined
2024e2.39 undefined0 undefined-0.12 undefined
20230.41 undefined-2.27 undefined-4.04 undefined
20220.53 undefined-1.53 undefined-1.98 undefined
20213.13 undefined1.44 undefined0.65 undefined
20202.56 undefined1.08 undefined0.78 undefined
20192.1 undefined-0.44 undefined-0.23 undefined
20180.63 undefined-1.79 undefined-1.59 undefined
20176.6 undefined2.57 undefined0.72 undefined
20160.92 undefined-9.47 undefined-8.89 undefined
20159.41 undefined-6.12 undefined-3.5 undefined
20143.51 undefined-15.22 undefined-7.13 undefined
20138.15 undefined-13.31 undefined-28.52 undefined
201210.46 undefined-15.96 undefined-22 undefined
201136.84 undefined-21.49 undefined-20.72 undefined
201036.17 undefined-72.06 undefined-73.87 undefined
2009172.68 undefined29.07 undefined0.96 undefined
2008154.52 undefined-88.05 undefined-102.84 undefined
2007195.93 undefined-5.91 undefined-28.67 undefined
200692.19 undefined-127.13 undefined-162 undefined
200562.23 undefined-120.1 undefined9.27 undefined
200413.11 undefined-278.93 undefined-281.93 undefined

XOMA Royalty business model

XOMA Corp is an American biotechnology company based in Berkeley, California, focused on drug development. The company was founded in 1981 by a team of scientists specializing in therapeutic antibodies. Since then, XOMA has become a leading research and development partner for many well-known pharmaceutical companies. XOMA's business model is based on collaboration with other companies and the exploration of antibody modules. As a research company, XOMA works with pharmaceutical companies that provide financial and personnel resources to advance drug research and development. XOMA, in turn, brings its extensive expertise to the collaborative work and supplies antibody modules suitable for both clinical use and research in the medical industry. To support technical collaboration, XOMA specializes in several areas. The focus is on the development of antibodies, proteins, and other molecules that can be used in medical metabolic regulation. The company also produces biological products used in clinical development, research, and analysis. Another important area for XOMA is the production and development of therapeutic antibodies. These antibodies are crucial tools in the field of medicine and are used to treat cancer, autoimmune diseases, and infectious diseases. XOMA has developed a wide range of products, including antibodies for the treatment of diabetes, cancer, and inflammatory diseases. XOMA also has a long history in the production of proteins and other therapeutic molecules. The company has unique technical capabilities for large-scale production of proteins, antibodies, and other molecules. These capabilities enable the company to play a significant role in the development of new drugs. In recent years, XOMA has also ventured into the field of medical robotics and technology, making significant investments in this area. The company is working on the development of robots and other technologies aimed at enabling effective diagnosis and treatment of diseases. In summary, XOMA is a successful biotechnology company specializing in collaboration with other companies and the exploration of antibody modules. The various business areas focused on the development of antibodies, proteins, and other molecules make XOMA an important partner for the pharmaceutical industry. XOMA Royalty is one of the most popular companies on Eulerpool.com.

XOMA Royalty SWOT Analysis

Strengths

XOMA Corp has a strong portfolio of biopharmaceutical products, which gives the company a competitive advantage in the market.

The company has a well-established research and development department, enabling them to continuously innovate and develop new drugs.

XOMA Corp has a robust intellectual property portfolio, providing protection and exclusivity for their products.

Weaknesses

The company heavily relies on a limited number of key products, potentially leaving them vulnerable to market fluctuations and patent expirations.

XOMA Corp faces tough competition from other biopharmaceutical companies, requiring continuous efforts to differentiate themselves.

The company has a relatively small marketing and sales team, which may limit their reach and penetration into new markets.

Opportunities

The global biopharmaceutical market is growing rapidly, providing an opportunity for XOMA Corp to expand their market share.

Increasing research in biotechnology and personalized medicine opens doors for the development of new therapies, which XOMA Corp can capitalize on.

Collaboration with other pharmaceutical companies or research institutions can lead to strategic partnerships and synergies.

Threats

Regulatory challenges in the biopharmaceutical industry, such as stricter FDA regulations, can impact XOMA Corp's product development and approval processes.

Global economic downturns and financial crises may affect healthcare budgets and reduce demand for XOMA Corp's products.

The emergence of generic drug manufacturers and biosimilar competition pose a threat to XOMA Corp's market share and pricing power.

XOMA Royalty Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

XOMA Royalty historical P/E ratio, EBIT multiple, and P/S ratio

XOMA Royalty shares outstanding

The number of shares was XOMA Royalty in 2023 — This indicates how many shares 11.471 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue XOMA Royalty earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates XOMA Royalty's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of XOMA Royalty’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating XOMA Royalty's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

XOMA Royalty stock splits

In XOMA Royalty's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for XOMA Royalty.

XOMA Royalty latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.45 -1.59  (-256.98 %)2024 Q3
6/30/2024-0.27 0.84  (407.69 %)2024 Q2
3/31/2024-0.83 -0.86  (-4.09 %)2024 Q1
12/31/2023-0.37 -0.49  (-32.72 %)2023 Q4
9/30/2023-0.49 -0.6  (-22.55 %)2023 Q3
6/30/2023-0.53 -0.45  (14.5 %)2023 Q2
3/31/2023-0.51 -0.62  (-22.68 %)2023 Q1
12/31/2022-0.48 -0.63  (-31.41 %)2022 Q4
9/30/2022-0.23 -0.48  (-104.6 %)2022 Q3
6/30/2022-0.17 -0.53  (-218.13 %)2022 Q2
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the XOMA Royalty stock

Eulerpool World ESG Rating (EESG©)

52/ 100

🌱 Environment

58

👫 Social

41

🏛️ Governance

57

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

XOMA Royalty shareholders

%
Name
Stocks
Change
Date
31.05763 % BVF Partners L.P.3,633,74306/30/2024
9.36573 % Fidelity Management & Research Company LLC1,095,790-5,8166/30/2024
4.02014 % BlackRock Institutional Trust Company, N.A.470,35627,8076/30/2024
3.55683 % The Vanguard Group, Inc.416,14910,6166/30/2024
2.13785 % Stonepine Capital Management, LLC250,129-3,6416/30/2024
2.13675 % Opaleye Management Inc.250,00006/30/2024
1.55216 % Geode Capital Management, L.L.C.181,60311,5546/30/2024
1.34379 % Morgan Stanley Investment Management Inc. (US)157,2249,6756/30/2024
1.20601 % State Street Global Advisors (US)141,1032,1546/30/2024
1.05297 % Acuitas Investments LLC123,19706/30/2024
1
2
3
4
5
...
10

XOMA Royalty Executives and Management Board

Mr. Thomas Burns(49)
XOMA Royalty Chief Financial Officer, Senior Vice President - Finance
Compensation 1.01 M
Mr. Jack Wyszomierski(67)
XOMA Royalty Independent Chairman of the Board
Compensation 164,684
Mr. Joseph Limber(70)
XOMA Royalty Independent Director
Compensation 159,799
Ms. Heather Franklin(57)
XOMA Royalty Independent Director
Compensation 154,799
Mr. Matthew Perry(50)
XOMA Royalty Independent Director
Compensation 152,299
1
2

Most common questions regarding XOMA Royalty

What values and corporate philosophy does XOMA Royalty represent?

XOMA Corp represents values of innovation, collaboration, and integrity in the biotechnology industry. With a strong corporate philosophy focused on advancing the discovery and development of transformative medicines, XOMA Corp strives to improve patients' lives through its cutting-edge research and development efforts. By fostering strategic partnerships and utilizing its expertise in antibody discovery and optimization, XOMA Corp aims to address significant medical challenges and deliver meaningful solutions. The company's commitment to scientific excellence, ethical practices, and patient-centric approach truly defines their values and corporate philosophy. Through their dedication, XOMA Corp continues to make a positive impact in the field of biotechnology.

In which countries and regions is XOMA Royalty primarily present?

XOMA Corp is primarily present in the United States.

What significant milestones has the company XOMA Royalty achieved?

XOMA Corp has achieved several significant milestones. The company successfully developed and commercialized XOMA 357, a potent antibody, for the treatment of patients with rare genetic disorders. XOMA Corp also reached important partnerships and collaborations with leading pharmaceutical companies, expanding its pipeline and reaching broader markets. Moreover, XOMA Corp has been granted multiple patents for their innovative technologies and therapeutic approaches. These achievements solidify XOMA Corp's commitment to medical advancements and its position as a key player in the biopharmaceutical industry.

What is the history and background of the company XOMA Royalty?

XOMA Corp, a renowned biotech company, has a rich history and an impressive background. Established in 1981, XOMA has been at the forefront of developing innovative antibody-based therapeutics. Initially focusing on hybridoma technology, the company rapidly advanced into antibody discovery and optimization. Over the years, XOMA has established strategic collaborations with leading pharmaceutical companies, enabling them to expand their research and development efforts. With a strong emphasis on novel drug discovery, XOMA has successfully developed multiple therapeutic candidates, particularly in the areas of immunology and inflammation. With its distinguished track record, XOMA Corp stands as a pioneering force in the biotech industry, consistently striving for breakthrough medical advancements.

Who are the main competitors of XOMA Royalty in the market?

The main competitors of XOMA Corp in the market are companies such as BioMarin Pharmaceutical Inc., Amgen Inc., and Regeneron Pharmaceuticals Inc.

In which industries is XOMA Royalty primarily active?

XOMA Corp is primarily active in the biotechnology industry.

What is the business model of XOMA Royalty?

XOMA Corp operates under a biotech business model. The company focuses on developing innovative therapeutics to address unmet medical needs. XOMA Corp utilizes its proprietary antibody discovery and optimization technologies to create potential breakthrough drugs for various diseases, including immunology, oncology, and metabolic disorders. By leveraging strategic partnerships and collaborations, XOMA Corp seeks to advance its pipeline of therapeutic candidates and bring them to market. With its strong emphasis on research and development, XOMA Corp aims to revolutionize healthcare by providing effective treatment options for patients worldwide.

What is the P/E ratio of XOMA Royalty 2024?

The XOMA Royalty P/E ratio is -244.92.

What is the P/S ratio of XOMA Royalty 2024?

The XOMA Royalty P/S ratio is 12.52.

What is the Quality Investing of XOMA Royalty?

The Quality Investing for XOMA Royalty is 2/10.

What is the revenue of XOMA Royalty 2024?

The expected XOMA Royalty revenue is 28.01 M USD.

How high is the profit of XOMA Royalty 2024?

The expected XOMA Royalty profit is -1.43 M USD.

What is the business model of XOMA Royalty

The XOMA Corporation is a biotechnology company that focuses on the discovery and development of new drugs. Its business activities can be divided into four main divisions: research and development, licensing, production, and clinical testing. Research and development is one of the key pillars of XOMA. The company utilizes an innovative technology platform to develop new drugs. It employs the so-called antibody technology, which enables the development of drugs targeting specific cancer cells, autoimmune reactions, and infectious diseases. Licensing of technologies is also an important component of XOMA's business model. The company's technology platform allows for the development of novel antibodies for diagnosing and treating diseases. Other companies can utilize this technology by paying licensing fees. Production is another crucial factor at XOMA. The company owns a bioreactor production facility capable of producing antibodies on a large scale. This allows the company to manufacture its own drugs in large quantities. It is also possible to license the production level to other companies. Last but not least, clinical testing plays a central role at XOMA. After the development of new drugs, they must undergo clinical testing to confirm their efficacy and safety. XOMA also utilizes these testing phases to set medical standards and expand its own portfolio. XOMA currently possesses several products available on the market and used in the treatment of various diseases. The most well-known product is Hieronymus, a drug for treating numerous autoimmune diseases, including rheumatoid arthritis. Other products include Gevokizumab, a drug for treating non-infectious inflammatory diseases, XOMA 358, a drug for treating hyperinsulinism, and Erenumab, a drug for migraines. In summary, XOMA Corporation's business model is suitable for establishing the company as a key player in the biotechnology and pharmaceutical industries. Through constant innovation, technology licensing, and clinical testing, it is possible to bring new drugs to the market and expand the company's product portfolio.

What is the XOMA Royalty dividend?

XOMA Royalty pays a dividend of 0 USD distributed over payouts per year.

How often does XOMA Royalty pay dividends?

The dividend cannot currently be calculated for XOMA Royalty or the company does not pay out a dividend.

What is the XOMA Royalty ISIN?

The ISIN of XOMA Royalty is US98419J2069.

What is the XOMA Royalty WKN?

The WKN of XOMA Royalty is A2ATUH.

What is the XOMA Royalty ticker?

The ticker of XOMA Royalty is XOMA.

How much dividend does XOMA Royalty pay?

Over the past 12 months, XOMA Royalty paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, XOMA Royalty is expected to pay a dividend of 0 USD.

What is the dividend yield of XOMA Royalty?

The current dividend yield of XOMA Royalty is .

When does XOMA Royalty pay dividends?

XOMA Royalty pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of XOMA Royalty?

XOMA Royalty paid dividends every year for the past 0 years.

What is the dividend of XOMA Royalty?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is XOMA Royalty located?

XOMA Royalty is assigned to the 'Health' sector.

Wann musste ich die Aktien von XOMA Royalty kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of XOMA Royalty from 11/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/8/2024.

When did XOMA Royalty pay the last dividend?

The last dividend was paid out on 11/8/2024.

What was the dividend of XOMA Royalty in the year 2023?

In the year 2023, XOMA Royalty distributed 0 USD as dividends.

In which currency does XOMA Royalty pay out the dividend?

The dividends of XOMA Royalty are distributed in USD.

All fundamentals about XOMA Royalty

Our stock analysis for XOMA Royalty Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of XOMA Royalty Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.